ResourceDrug Discovery & Development
How low can you go? A new era of sensitivity in Octet BLI
22 Oct 2026This application note explores advances in biolayer interferometry (BLI) sensitivity for studying biomolecular interactions, with a focus on generating accurate kinetic and affinity measurements at low response levels. Learn how factors including assay buffer, ligand density, mass transport, double reference subtraction and avidity can influence data quality. Discover how enhanced BLI sensitivity can support the analysis of low-abundance analytes, reduce sample requirements and enable reliable characterization across molecules ranging from antibodies to smaller proteins and peptides.
Resource details:
Resource type: Application note
Page count: 10
Read time: 8 mins
Related products
Request Quote for All Products
Links
Tags
Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.High-Throughput ScreeningHigh-throughput screening (HTS) is an automated drug discovery technique for identification of active compounds against a compound library. Use HTS readers and integrated assay preparation / analysis workstations to screen your compounds. Identify active compounds against various HTS libraries, including membranes, proteins and peptides and HTS cell lines. Find the best high-throughput screening products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Biophysical Characterization